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Background: Acne is a multifactorial disease exhibiting
distinct clinical presentations. Among them, the catamenial
type is a matter of concern for young women. Some oral
contraceptives may help without, however, clearing the skin
condition.
Aim: The present open study aimed at evaluating the effect
of overnight applications of a paste made of petrolatum,
15% zinc oxide and 0.25% miconazole nitrate.
Method: The split-face trial was conducted in 35 women. A
non-medicated cream was used as control. Clinical evalua-
tions and biometrological assessments on cyanoacrylate
follicular biopsies were performed monthly for 3 months.
Comedometry and the density in autofluorescent follicular
casts were used as analytical parameters. In addition, the
five most severe cases at inclusion were tested at the
completion of the study for follicular bacterial viability using
dual flow cytometry.
Results: Compared with baseline and to the control hemi-
face, the medicated paste brought significant improvement
of acne. The number of papules and their redness were re-
duced beginning with the first treatment phase. A reduction
in the follicular fluorescence was yielded beginning with the
second treatment phase. The ratios between injured and dead
bacteria, on the one hand, and live bacteria, on the other hand
were significantly increased at completion of the study.
Conclusion: A miconazole paste applied for 1 week at the
end of the ovarian cycle has a beneficial effect on catame-
nial acne.
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ACNE VULGARIS is one of the most common skindiseases. It has a mulifactorial origin affect-
ing some of the pilosebaceous follicles of the face
and trunk, particularly in adolescents and young
adults. Increased sebum production, Propionibac-
terium acnes hypercolonization, comedo forma-
tion and follicular inflammation are obviously
involved in the lesions (1). However, the precise
inflammatory pathogenesis is not entirely under-
stood (2). This is particularly the case for recur-
rent catamenial acne, which cannot be explained
by sudden changes in the recognized factors
underlying acne vulgaris. There is much varia-
tion in the age of onset and the age of resolution
of catamenial acne. Most often, it remains mild in
severity. However, the perceived psychosocial
impairment, which is highly subjective (3), is
not unfrequently influenced by overrating acne
severity by the affected young women.
Currently, there is a variety of topical and
systemic drugs that counteract the main aspects
of acne pathology. However, none of them targets
specifically catamenial acne with the exception of
some oral contraceptives. Usually, these pharma-
cological agents only bring slow improvement
without completely clearing the disease (4–7).
There is also much variation in the response of
women to acne therapy. The success of the treat-
ment depends on both the selection of the appro-
priate medications and the compliance of the
subject. Oral isotretinoin is contra-indicated in
women with catamenial acne. Continuous cures
of oral antibiotics show efficacy (8, 9), but they
are not recommended due to bacterial resistance
that may occur during long-term treatment (8–
10). Most of the classical topical treatments bring
no satisfactory inhibition of the crops of catame-
nial acne, most probably because they are applied
for a too short period of time. In addition, they
target pathomechanisms that are not directly
responsible for the specific presentation of cata-
menial acne. Hence, it would be advisable to look
for safe topical formulations that could bring a
fast relief of inflammatory acne papules without
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necessarily acting upon the underlying chronic
acne-prone status.
The present clinical and bioinstrumental study
aimed at assessing the effect of a non-steroidal,
antibiotic-free anti-inflammatory paste on cata-
menial acne resistant to oral contraceptives.
Patients and Methods
This open, single center, outpatient study was
conducted in accordance with the Declaraton of
Helsinki. The protocol was reviewed by the local
Ethics Committee. A total of 35 students and
qualified nurses aged from 19 to 25 years were
enrolled after giving their written informed con-
sent. All the patients complained from mild acne
corresponding to grades 2 or 3 according to the
Leeds revised acne grading system (11). The
medical history was reviewed for each volunteer
and did not reveal any other relevant finding. All
the volunteers suffered from acne lesions recur-
ring in catamenial crops for at least 2 years. They
were on oral contraceptive for 10 months to 7
years. The current pills contained the 19-nortes-
toserone derivatives desogestrel or gestodene,
which had been shown to improve acne in pre-
vious clinical studies (4, 5).
The oral contraceptive was kept unchanged
while the volunteers entered a 3-month split-
face assessment of the effect of a medicated paste
on the inflammatory acne papules. The paste
made of petrolatum, 15% zinc oxide and 0.25%
miconazole nitrate (Zimycans, Barrier Therapeu-
tics, Geel, Belgium). Concomitant treatments tar-
getting acne were prohibited. The test medication
was applied once daily in the evening for 1 week
on a randomized hemiface; the treatment started
from day 24 of the ovarian cycle to end on day 2
of the following one. The symmetrical facial area
received an unmedicated formulation (Eucerins,
Beiersdorf, Brussels, Belgium) to serve as control
for any placebo effect. The ingredients are listed in
Table 1. Clinical and bioinstrumental assessments
were performed monthly at day 3 of each cycle.
Acne papules were counted. Their redness
was measured using an advanced version of the
Visi-Chroma (Biophotonics, Lessines, Belgium).
As shown using an older version (12), this device
allows to measure skin colors, in particular para-
meter a* on small spots. The median value of all
the papules was calculated. Cyanoacrylate skin
surface strippings (CSSS) were used to collect
follicular casts as previously described (4, 8,
13–17). In short, they were collected from both
cheeks using plastic strips (Melinex Os, Imperial
Chemical Industries, London, UK) coated with
cyanoacrylate adhesive (Superglues, Loctite,
Brussels, Belgium). Image analysis was per-
formed on these CSSS following the comedome-
try procedure (4, 8, 13–17) in order to assess the
microcomedo density and their cumulative size/
cm2 of skin surface. An indication of the amount
of P. acnes was also determined on the same CSSS
by detecting the porphyrin-induced follicular
fluorescence (18, 19). The percentage of fluores-
cent follicular casts seen under fluorescence mi-
croscopy was calculated. In addition, the five
most severe acne cases at inclusion (i.e. exhibiting
more than 20 papules on the face) were selected
for quantitative microbiology. This procedure
was applied as previously described (4, 8) to the
CSSS harvested at the last evaluation session. In
short, the follicular casts were scraped from the
CSSS using a sterile scalpel. The collected mate-
rial was dispersed in sterile PBS before filtering
through a gauze to remove clumps of corneo-
cytes. Equal volumes of the two fluorescent
reagents of the live/deads Baclight bacterial
viability kit (L-7012, Molecular Probe Europe,
Leiden, The Netherlands) were mixed thor-
oughly. An aliquot of 3mL/mL of this solution
was added to the suspension of bacteria and
small debris of cornified material. After incuba-
tion at room temperature for 15 min, the material
was submitted to dual flow cytometry.
Fluorescence data from both live (green fluor-
escence) and dead (red fluorescence) bacteria
were analyzed by a FACStar flow cell sorter
coupled with the lysys II software for data ana-
lysis (Becton-Dickinson, London, UK). Green




















fluorescence values measured at 530 nm were
plotted against red fluorescence values measured
at 620 nm. Data were analyzed for the percen-
tages of live bacteria, dead bacteria and injured
bacteria. The ratios of injured-to-live bacteria,
and of dead-to-live bacteria were evaluated.
Missing evaluations were replaced using the
‘Last Observation Carried Forward’ (LOCF)
method. The data distributions were skewed.
Hence, the medians and percentiles 20 (P20)
and 80 (P80) were determined. Proportions
were calculated to describe the changes from
baseline. For both test sites and each parameter,
the differences between median values calculated
at each cycle were tested for significance using
the paired non-parametric Friedman and Dunn
tests. At each evaluation time, the differences and
the Wilcoxon-matched paired test were used to
compare parameters between the two topically
treated sites. All results were considered to be
significant at the 5% critical level (Po0.05).
Results
At inclusion in the study, no difference was
present in any of the evaluation parameters
between the hemifaces ascribed for receiving
the given products. All the 35 volunteers com-
pleted the study, but a total of six visits were
missing because the defined days of assessment
was not respected by the volunteers. The toler-
ance of both products was excellent with any sign
of intolerance and any complaint of discomfort.
Some significant changes were yielded in time
in the values of the evaluation parameters.
Compared with baseline, the number of pa-
pules was already decreased after the first treat-
ment cycle (Po0.05), and the improvement was
further increased (Po0.01) after the second and
third cycles (Fig. 1). No significant changes were
yielded at the control sites. The difference be-
tween the two hemifaces reached significance
(Po0.01) since the first treatment period.
Compared with baseline a* values, the erythe-
ma was significantly decreased after one treat-
ment period (Po0.01) and further on (Po0.001)
(Fig. 2). No significant changes were present on
the control hemiface. The reduction in the para-
meter a* at the treated sites compared with the
control site was highly significant (Po0.001) after
each of the three treatment phases.
The Friedman test indicated a significant change
in both the number (Po0.05) and cumulative
size (Po0.01) of follicular casts during treat-
ment, but the Dunn post-test failed to identify a
specific time of efficacy. No variations in time
of these parameters were disclosed on the control
site. The comparison between the two hemifaces
indicated a significant decrease (Po0.01) in
both the number and cumulative size of follicular
casts beginning at the second treatment phase
(Figs 3 a, b).
Compared with baseline values, the percentage
of fluorescent follicular casts was significantly
reduced after two (Po0.05) and three (Po0.001)
treatment phases (Fig. 4). By contrast, the control
area showed an increase in the percentage of
fluorescent follicles between baseline and the
second month (Po0.01), and between the first
and the second month (Po0.05). The difference
between the two hemifaces was signifi-
cant (Po0.0001) beginning the second month of
treatment.
Data on flow cytometry assessments are pre-
sented in Table 2. The median value in the
injured-to-live bacteria ratio reached 66% and
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Fig. 1. Median number (N) of acne papules on the hemifaces treated
by the medicated paste (T) or receiving the non-medicated preparation
(C). Intersite difference ***Po0.01.
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Fig. 2. Erythema of the acne papules measured by the parameter a* on
the hemifaces treated by the medicated paste (T) or receiving the non-
medicated preparation (C). Intersite difference ***Po0.001.
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25% on the treated and control hemifaces, respec-
tively. The median value in the dead-to-living
bacteria ratio reached 84% and 14% on the trea-
ted and control hemifaces, respectively. The
differences between each of these two assess-
ments reached significance (Po0.01).
Discussion
Compliance is undoubtedly one important rea-
son for treatment failures of acne. The presently
tested formulations were well tolerated and the
overnight applications did not interfere signifi-
cantly with the individual life-styles of the pa-
tients. Compliance was much better than that
experienced with many other topical anti-acne
therapies.
It is accepted that a placebo or vehicle effect in
acne trials can be as high as 40% (20, 21). There is
also a natural background variation in the ther-
apeutic response of milder acne forms including
catamenial acne. Psychological factors indepen-
dent of other aggravating or precipitating factors
are also operative in the disease evolution. In-
deed, some improvement may occur in indivi-
duals when they are seeking treatment, and when
they expect to get better (20). Such a complexity
in the acne process incited us to conduct an intra-
individual comparison of two topical products
using the split-face method. Thus we expected to
minimize many of the intercurrent uncontrolled
confounding factors.
Some reports (20) and our own experience
suggest that the average duration of inflamma-
tory papules in young women run over about 10
days. The severity of catamenial acne seems to
peak in the very first days of the ovarian cycle in
parallel with variation in the sebum excretion (22,
23). Hence, the trial planned a 1-week topical
treatment followed by assessments early in the
course of the ovarian cycle.
The medicated paste contained miconazole
nitrate, which is a time-honored compound ac-
tive against many fungi including Malassezia
yeasts, and against many gram-positive bacteria
including Staphylococcus spp. and P. acnes (24, 25).
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Fig. 3. Microcomedones on the hemifaces treated by the medicated
paste (T) or receiving the non-medicated preparation (C). a, density; b,
cumulative size. Intersite difference **Po0.01.
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Fig. 4. Percentage of fluorescent microcomedones on the hemifaces
treated by the medicated paste (T) or receiving the non-medicated
preparation (C). Intersite difference ***Po0.001.
TABLE 2. Dual flow cytometry assessment of intrafollicular bacterial viability at completion of the study in the five most severely affected patients at inclusion
Patient
Injured/live bacteria (%) Dead/live bacteria (%)
Treated Control Treated Control
1 40.1/23.3 (172) 28.4/37 (77) 30.8/23.3 (132) 18.6/37 (50)
2 29.9/45.4 (66) 13.5/73.3 (18) 21.5/45.4 (47) 10.2/73.3 (14)
3 8.7/66.7 (13) 10.1/81.2 (12) 20.6/66.7 (31) 3.6/81.2 (4)
4 35.0/33.4 (165) 31.2/37.2 (84) 28.2/33.4 (84) 24.1/37.2 (65)
5 15.9/30.4 (52) 17.4/68.4 (25) 44.8/30.4 (147) 6.3/68.4 (9)
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All these microorganisms may be involved in
acne and acne-related disorders (2, 26, 27). The
present study shows that the paste was signifi-
cantly more effective in acne than the non-medi-
cated cream. A similar paste formulation was
previously tested with success in other inflam-
matory dermatoses (28). In this study, the anti-
inflammatory properties of the paste appeared to
be one important facet involved in the rapid
resolution of papular lesions. The seemingly
comedolytic effect is more puzzling because no
specific and direct effect can be expected in
intercorneocyte binding from the components of
the medicated paste. This is at variance with
other products (16, 17). An indirect and yet
undisclosed effect might be operative.
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